INTERVIEW: Oncology central as Takeda extends global reach
This article was originally published in Scrip
Executive Summary
Takeda has been positioning oncology as a major area of investment and growth since its $8.8bn acquisition of the US firm Millennium in 2008, with expectations that a stronger presence would help it face the loss of exclusivity for blockbuster antidiabetic Actos (pioglitazone) and bolster its presence in a critical therapeutic area.